Sage Therapeutics took an 18.8 percent dive to USD 59.15 in the US pre-market after the US biotech firm generated disappointing results from a trial involving a potential treatment for severe depression.
Bloomberg News highlights that this late-stage trial, completed in collaboration with Biogen, reached its primary endpoint with improved depression symptoms, whereas the long-term effect was one of the major concerns ahead of the trial results being published.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.